Cost of Monitoring Patients Treated With Vitamin K Antagonists in Spain

Cost of Monitoring Patients Treated With Vitamin K Antagonists in Spain

To estimate annualized total cost rates (i.e. direct medical costs from hospitalizations, consultations, medications, and tests) of adequately controlling a patient (i.e. INR between 2-3 and TTR≥ 60%) diagnosed with non-valvular atrial fibrillation (NVAF) or venous thromboembolism (VTE), and treated with vitamin K antagonists (VKA) in Spain.

For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com

Inclusion Criteria:

• Patients aged 18 or older over the study period
• Patients with a diagnosis for NVAF or VTE anytime in their medical records
• Patients having at least one year of enrolment in the database prior to the index date
• Patients newly initiated with VKA during the study period (index date)

Exclusion Criteria:

• Patients with a diagnosis for both NVAF and VTE anytime in their medical records